Talent
Investor Portal
About
What We Do
FAQs
Sectors
Deep Tech
Life Sciences
Health Tech
Portfolio
Team
News
Contact
Newsroom
latest news from ose
and across our portfolio
Featured News
August 31, 2023
Oxford Science Enterprises Appoints Ed Bussey as Chief Executive Officer
Article links to www.globenewswire.com
September 27, 2023
Sitryx raises additional $39 million to progress development of disease-modifying therapeutics
Article links to prn.to
October 3, 2023
The Oxford-Harrington Rare Disease Centre Launches
Article links to www.beacontx.com
June 12, 2023
Beacon Therapeutics launches with £96 million to develop a new generation of gene therapies for retinal diseases
Article links to innovation.ox.ac.uk
May 22, 2023
Oxford University retains No. 1 spot for spinouts
Article links to www.ultromics.com
April 26, 2023
Ultromics granted FDA Breakthrough Device Designation
Article links to www.caristo.com
April 17, 2023
Caristo Diagnostics Completes Series A Financing and Welcomes New CEO
Article links to quantummotion.tech
February 21, 2023
Quantum Motion Raises £42 Million Investment Round
All News
09•12•23
Portfolio News
Scenic Biotech
Scenic Biotech Announces Positive Preclinical Data for its QPCTL Inhibitor SC-2882
01•02•23
Portfolio News
Scenic Biotech
Scenic Biotech enters cooperative research and development agreement with the National Institutes of Health for genetic modifier-based treatment approach for Niemann-Pick Type C Disease
20•01•23
Portfolio News
Scenic Biotech
Scenic Biotech strengthens drug discovery expertise in management team with the addition of Kristof Van Emelen
23•10•22
Portfolio News
Scenic Biotech
Scenic Biotech appoints Jens Würthner as Chief Medical Officer
29•03•22
Portfolio News
Scenic Biotech
Scenic Biotech and the Barth Syndrome Foundation announce partnership to explore genetic modifiers to find tailored treatment for complex rare disease
10•03•22
Portfolio News
Scenic Biotech
Scenic Biotech announces $31 million financing to progress pipeline of genetic modifiers in cancer and rare diseases
02•02•21
Portfolio News
Scenic Biotech
Scenic Biotech appoints Dr. Philippe Dro as Independent Chairman
20•09•20
Portfolio News
Scenic Biotech
Scenic Biotech enters into genetic modifier collaboration with Genentech
Menu
About
What We Do
FAQs
Sectors
Deep Tech
Life Sciences
Health Tech
Portfolio
Team
News
Contact
Talent
Investor Portal